Cassava lays off 3rd of workforce in wake of phase 3 Alzheimer's fail

Cassava Sciences is laying off 10 employees—a third of its workforce—as the biotech seeks to conserve cash in the wake of the phase 3 fail of its lead Alzheimer’s disease drug.